Maxim Group Upgrades Cyclo Therapeutics to Buy, Announces $4 Price Target
Portfolio Pulse from Benzinga Newsdesk
Maxim Group analyst Jason McCarthy has upgraded Cyclo Therapeutics (NASDAQ:CYTH) from Hold to Buy and set a price target of $4.
September 27, 2023 | 1:35 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cyclo Therapeutics has been upgraded to Buy from Hold by Maxim Group, with a price target of $4.
The upgrade from Hold to Buy by Maxim Group indicates a positive outlook for Cyclo Therapeutics. The price target of $4 suggests that the analyst believes the stock has potential for growth. This could lead to increased investor interest and a potential rise in stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100